Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of “Hold” by Analysts

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have been assigned a consensus recommendation of “Hold” from the five research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.50.

A number of research firms have recently issued reports on ANIX. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Finally, Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th.

Anixa Biosciences Stock Performance

Shares of ANIX stock traded down $0.02 during mid-day trading on Tuesday, hitting $3.03. 131,546 shares of the stock traded hands, compared to its average volume of 164,871. The firm has a market cap of $103.08 million, a price-to-earnings ratio of -9.77 and a beta of 0.59. The company’s 50-day simple moving average is $2.79 and its 200-day simple moving average is $2.91. Anixa Biosciences has a twelve month low of $2.32 and a twelve month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. Analysts forecast that Anixa Biosciences will post -0.31 earnings per share for the current year.

Insider Buying and Selling at Anixa Biosciences

In related news, CEO Amit Kumar acquired 21,000 shares of the stock in a transaction on Friday, June 12th. The shares were purchased at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the purchase, the chief executive officer directly owned 630,812 shares in the company, valued at approximately $1,577,030. The trade was a 3.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 26.40% of the company’s stock.

Institutional Trading of Anixa Biosciences

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after purchasing an additional 3,645 shares during the last quarter. Prosperity Wealth Management Inc. increased its stake in Anixa Biosciences by 14.5% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after buying an additional 5,300 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Anixa Biosciences by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after buying an additional 7,271 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Anixa Biosciences by 13.6% during the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after buying an additional 7,300 shares in the last quarter. Finally, Westside Investment Management Inc. boosted its stake in shares of Anixa Biosciences by 25.7% in the 4th quarter. Westside Investment Management Inc. now owns 44,000 shares of the company’s stock worth $137,000 after buying an additional 9,000 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.